Vyome Holdings, Inc PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Vyome Holdings, Inc pe ratio for the quarter ending 2026-06-30 was -1.38, a change of 16.2 year-over-year.
- Vyome Holdings, Inc pe ratio for the quarter ending 2026-03-31 was -1.4, a change of 0.35 year-over-year.
- Vyome Holdings, Inc pe ratio for the quarter ending 2025-12-31 was -1.97.
- Vyome Holdings, Inc pe ratio for the quarter ending 2025-09-30 was -1.48, a change of 64.5 year-over-year.
- Vyome Holdings, Inc pe ratio for fiscal 2026 was -1.38.
- Vyome Holdings, Inc pe ratio for fiscal 2025 was -1.97.
- Vyome Holdings, Inc pe ratio for fiscal 2024 was -65.99.
- Vyome Holdings, Inc pe ratio for fiscal 2023 was -51.5, a change of 387.7 from fiscal 2022.
- Available history
- 2016-12-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |